Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Decrease in Short Interest

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the target of a large drop in short interest in December. As of December 15th, there was short interest totalling 681,400 shares, a drop of 18.4% from the November 30th total of 835,500 shares. Based on an average trading volume of 190,300 shares, the days-to-cover ratio is presently 3.6 days. Currently, 3.5% of the company's stock are short sold.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. William Blair assumed coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They set an "outperform" rating for the company. JMP Securities reiterated a "market outperform" rating and issued a $22.00 target price on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Wedbush boosted their target price on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $17.00 price target on shares of Vigil Neuroscience in a research report on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Vigil Neuroscience currently has an average rating of "Buy" and an average price target of $19.75.

Vigil Neuroscience Stock Performance

VIGL stock traded down $0.01 during mid-day trading on Friday, hitting $1.65. The company had a trading volume of 202,764 shares, compared to its average volume of 244,499. The firm has a market cap of $67.45 million, a PE ratio of -0.80 and a beta of 1.65. Vigil Neuroscience has a 12 month low of $1.54 and a 12 month high of $6.06. The stock's fifty day moving average price is $2.80 and its two-hundred day moving average price is $3.40.

Institutional Investors Weigh In On Vigil Neuroscience

Hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC purchased a new stake in Vigil Neuroscience in the second quarter worth $26,000. Renaissance Technologies LLC increased its holdings in Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company's stock worth $286,000 after acquiring an additional 11,536 shares during the last quarter. Ensign Peak Advisors Inc lifted its holdings in Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company's stock valued at $1,580,000 after purchasing an additional 166,442 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vigil Neuroscience during the second quarter valued at about $87,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Vigil Neuroscience in the second quarter worth about $5,940,000. Institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.